A Clinically Practical Nomogram for Predicting Survival in Elderly Patients ( /= 65 Years) With Bladder Urothelial Carcinoma: A Study Based on SEER Database and External Validation #MMPMID41331282
Wei J; Wei C; Chen J; Zhang X; Zhao W
Cancer Rep (Hoboken) 2025[Dec]; 8 (12): e70418 PMID41331282show ga
BACKGROUND: Bladder urothelial carcinoma is a common malignancy in the elderly, yet accurate prognostic tools for older patients remain limited. AIMS: This research aimed to create and validate nomogram predicting overall survival (OS) for elderly patients aged 65 years and older with urothelial carcinoma of the bladder (UCB). METHODS: We sourced 12702 UCB patients diagnosed between 2004 and 2015 from the Surveillance, Epidemiology, and End Results database. The patients were randomized into training (70%) and internal validation (30%) cohorts. In addition, 55 patients from Minzu Hospital of Guangxi Zhuang Autonomous Region between 2012 and 2022 were selected as the external validation cohort. Utilizing univariate and multivariate Cox regression analyses, we devised a nomogram forecasting 1-, 3-, and 5-year OS. Several metrics, including the consistency index (C-index), calibration plots, area under the receiver operator characteristics (ROC) curve, and decision curve analysis (DCA) were used to validate the validity and clinical utility of the nomogram. Patients were categorized into high- and low-risk profiles, and their survival outcomes were contrasted using the Kaplan-Meier method and the log-rank test. RESULTS: Age, race, marriage, AJCC stage, tumor size, surgery, radiotherapy, and chemotherapy were identified as independent prognostic factors of OS. In the training cohort, internal validation cohort and external validation cohort, the nomogram for predicting OS achieved C-index values of 0.673 (95% CI: 0.665-0.681), 0.672 (95% CI: 0.660-0.684), and 0.826 (95% CI: 0.732-0.920), respectively. In all cohorts, the calibration plots revealed high consistency between actual and predicted values. The nomogram depicted by ROC and DCA showcased superior stability, predictive value, and clinical applicability for 1, 3-, and 5-year OS. The risk stratification delineated patients into low- and high-risk brackets, revealing significant prognostic distinctions (p ? 0.05). CONCLUSIONS: Based on the SEER database and Chinese data, we developed a reliable nomogram forecasting 1-, 3-, and 5-year OS for older patients with UCB. The nomogram can identified high-risk and low-risk patients, aiding clinicians in personalised treatment and prognostic evaluations. This allows high-risk patients to receive intensive treatment or close follow-up, while low-risk patients can avoid overtreatment.
Cancer+Rep+(Hoboken) 2025 ; 8 (12): e70418
